Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.

CONCLUSIONS: Adding esaxerenone to existing renin-angiotensin system inhibitor therapy in patients with type 2 diabetes and microalbuminuria increased the likelihood of albuminuria returning to normal levels, and reduced progression of albuminuria to higher levels.
PMID: 33239409 [PubMed - as supplied by publisher]

Source: Clinical Journal of the American Society of Nephrology : CJASN - November 25, 2020 Category: Urology & Nephrology Authors: Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, Sawanobori T Tags: Clin J Am Soc Nephrol Source Type: research